Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology
Can Oncotype be used in women with ER positive, 1-3 lymph node positive disease with extracapsular extension?
Answer from: Medical Oncologist at Academic Institution
The use of Oncotype assay in 1-3 node positive women is addressed in RxPonder trial in which women with 1-3 positive nodes and oncotype scores of 25 or less were randomized to receive either endocrine versus chemoendocrine. The trial is fully enrolled but the results have been reported as yet. Ho...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
We recently published data on Recurrence Score (Oncotype) and ER+ breast cancer in men vs women (Massarweh, JCO 2018), that included 57000 women with ER positive breast cancer and 0-3 lymph nodes involved.Breast cancer specific mortality was very low in patients with oncotype score 0-30 (low/interme...
Answer from: Medical Oncologist at Academic Institution
The data for using Oncotype DX in N1 disease is still evolving as we await the results of the RxPONDER trial. The retrospective SWOG8814 data does seem to indicate that some N1 patients with scores <18 treated with endocrine therapy did as well as those treated with chemotherapy+endocrine therapy...
Answer from: Medical Oncologist at Community Practice
Based on NCCN guidelines, the recurrence score may be utilized in patients with 1-3 positive axillary lymph nodes as a discriminator of whether chemotherapy should be added to anti-estrogen therapy for patients with HR+/HER2- breast cancer. These are based on the retrospective analysis in S8814. In ...
Answer from: Medical Oncologist at Community Practice
Data from RxPonder (page 304) presented in SABCS 20 show no benefit for chemotherapy in 1-3+ LN and low/intermediate RS <25, consistent with the value of disease biology over stage. More data from the meeting that separate out stage vs. biology in patient outcome.